| Biotechnology Industry | Healthcare Sector | Yamin Mohammed Khan CEO | XMUN Exchange | - ISIN |
| GB Country | 301 Employees | - Last Dividend | 14 Dec 2012 Last Split | - IPO Date |
hVIVO plc operates as a pivotal entity within the pharmaceutical services and contract research sector, specializing in the testing of vaccines and antivirals through its innovative human challenge clinical trials. Formerly known as Open Orphan Plc, the company underwent a rebranding to hVIVO plc in October 2022, marking a new chapter in its evolution. Positioned strategically in London, United Kingdom, hVIVO extends its services to a diverse range of clients, including big pharmaceutical companies, biotechnology firms, government bodies, and public health organizations. Its commitment to advancing medical research and contributing to global health security is evident through its development and deployment of human challenge study models for a variety of conditions such as respiratory syncytial virus (RSV), influenza, human rhinovirus, asthma, malaria, cough, chronic obstructive pulmonary disease (COPD), and notably, COVID-19.
hVIVO is a pioneer in conducting human challenge studies, a research approach where volunteers are intentionally exposed to pathogens to study the effects of vaccines and antivirals. This includes a range of conditions such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, with an emerging focus on developing a COVID-19 human challenge study model.
The company boasts a specialized laboratory that offers a comprehensive suite of services designed to support the pre-clinical and clinical stages of respiratory drug and vaccine discovery and development. These services are crucial for understanding the virology and immunology aspects of drug development processes.
hVIVO provides an extensive array of research services that assist clients during the initial stages of drug and vaccine development. This spans from basic research to early clinical trials, ensuring that foundational studies are conducted with precision and expertise.
Apart from its core scientific activities, hVIVO also extends its expertise to sales and marketing, data management, and statistical analysis. These services are integral to the successful commercialization and broader application of research findings in the pharmaceutical industry.
The company offers specialized consultancy and services in drug development, guiding clients through the complexities of bringing a pharmaceutical product to market. This includes regulatory guidance, strategy development, and operational support, leveraging hVIVO's extensive industry experience.